L R Silverman
Affiliation: Mount Sinai School of Medicine
- Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group BLewis R Silverman
Division of Medical Oncology, Mount Sinai School of Medicine and Memorial Sloan Kettering Cancer Center, Box 1129, One Gustave L Levy Place, New York, NY 10029, USA
J Clin Oncol 20:2429-40. 2002..Supportive care is standard therapy. We previously reported that azacitidine (Aza C) was active in patients with high-risk MDS...
- SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromesFrancis J Giles
Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
Blood 102:795-801. 2003..Studies of other RTKI and/or other antiangiogenic approaches, with correlative studies to examine biologic effects, may be warranted in patients with AML/MDS...
- Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemiaHelene A Yuen
SUGEN Inc, South San Francisco, CA, USA
Leuk Res 28:679-89. 2004..The translational and clinical analyses described in this report provide some insights into the mechanism and duration of action of SU5416...
- Clinical roundtable monograph. Overall survival and maintenance of MDS patientsLewis R Silverman
Mount Sinai Medical Center, New York, New York, USA
Clin Adv Hematol Oncol 7:S3-5. 2009....
- Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS)L R Silverman
Division of Medical Oncology, Mount Sinai School of Medicine, New York, New York 10029, USA
Oncologist 6:8-14. 2001..Among the promising new agents are nucleoside analogues, such as 5-azacytidine and decitabine, which reactivate tumor suppressor gene transcription through effects on DNA methylation...
- Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agentsLewis R Silverman
Division of Hematology Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
Leuk Res 33:S18-21. 2009..Prolonged survival was independent of achieving complete response. Azacitidine in combination with histone deacetylase inhibitors might offer better efficacy by modulating the methylation and acetylation states of silenced genes...
- Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group BLewis R Silverman
Division of Hematology Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
J Clin Oncol 24:3895-903. 2006..We report the combined results of three previously reported clinical trials (n = 309) with azacitidine using the WHO classification system for MDS and acute myeloid leukemia (AML) and IWG criteria for response...
- The role of methyltransferase inhibitors in the management of the myelodysplastic syndromesLewis R Silverman
Division of Hematology/Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
Cancer Control 11:11-5. 2004
- DNA methyltransferase inhibitors in myelodysplastic syndromeLewis R Silverman
Division of Hematology Oncology, Department of Neoplastic Diseases, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1129, New York, NY 10029, USA
Best Pract Res Clin Haematol 17:585-94. 2004..Prolonged administration of azacitidine results in reactivation of normal hematopoiesis by its effect on inhibiting DNA methylation...
- Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromesLewis R Silverman
Department of Medicine Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
Cancer 117:2697-702. 2011....
- Methylation inhibitor therapy in the treatment of myelodysplastic syndromeLewis R Silverman
Myelodisplastic Syndrome/Myeloproliferative Disease Center, Mount Sinai School of Medicine, NewYork, NY, USA
Nat Clin Pract Oncol 2:S12-23. 2005..g. according to age, risk, classification, and cytogenetic profile), and the combination strategies, particularly with histone deacetylase inhibitors, in the management of MDS...
- Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420Sherif S Farag
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA
Clin Cancer Res 8:2812-9. 2002..Expression of NKG2D ligands by leukemic cells was detected in the majority of cases tested and should be assessed for correlation with response to IL-2 in future studies...
- Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B studyAlice B Kornblith
Women s Cancers Program, Dana Farber Cancer Institute, Rm D1210, 44 Binney Street, Boston, MA 02115, USA
J Clin Oncol 20:2441-52. 2002..The impact of azacytidine (Aza C) on the quality of life of 191 patients with myelodysplastic syndrome was assessed in a phase III Cancer and Leukemia Group B trial (9221)...
- CANCER AND LEUKEMIA GROUP B--MOUNT SINAILewis Silverman; Fiscal Year: 2002..With these associated investigators in 12 affiliated institutions, Mount Sinai plans to participate in all Group activities. ..